Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 112 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: FA Clear all
Active, not recruiting Not applicable Interventional

Study on Use of Omega-3 Fatty Acids to Improve Outcomes in Individuals With Sickle Cell Disease

NCT05758766
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Plant-based omega-3-FA
Dietary Supplement
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
5 Years to 18 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 20, 2026, 4:46 PM EDT
Completed No phase listed Observational Results available

Post- Surgery Recovery: Nerve Blocks w/ Sedation vs. Nerve Block w/ Either Sedation/Gen. Anesthesia

NCT02602080
View directory record Official record
Conditions
Nausea, Emesis
Interventions
Not listed
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 99 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2019 · Synced Oct 20, 2026, 4:46 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Omega-3 Fatty Acids and Subconcussive Head Impacts

NCT06736925
View directory record Official record
Conditions
Subconcussive Head Impact, Omega-3 Fatty Acids
Interventions
Omega-3 Fatty Acids (EPA plus DHA), Organic soybean oil, Soccer Heading Model
Dietary Supplement · Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 30 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Bloomington, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Phase 1 Interventional

Bone Marrow Cell Gene Transfer in Individuals With Fanconi Anemia

NCT00272857
View directory record Official record
Conditions
Fanconi Anemia
Interventions
Retrovirus Construct
Genetic
Lead sponsor
Boston Children's Hospital
Other
Eligibility
1 Year to 35 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 23, 2017 · Synced Oct 20, 2026, 4:46 PM EDT
Recruiting No phase listed Observational

Clinical Course Of Disease In Participants With FA-CM

NCT06865482
View directory record Official record
Conditions
Friedreich Ataxia, Cardiomyopathy
Interventions
Not listed
Lead sponsor
Lexeo Therapeutics
Industry
Eligibility
6 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
8
States / cities
La Jolla, California • Tampa, Florida • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 20, 2026, 4:46 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

FA Clinical Outcome Measures

NCT03090789
View directory record Official record
Conditions
Friedreich Ataxia, Neuro-Degenerative Disease
Interventions
Not listed
Lead sponsor
Friedreich's Ataxia Research Alliance
Other
Eligibility
4 Years to 80 Years
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2001 – 2030
U.S. locations
9
States / cities
Los Angeles, California • Denver, Colorado • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2024 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Phase 1 Interventional

Pilot Study of a Fluocinolone Acetonide Intravitreal Insert (FA-i) to Treat Intermediate-, Posterior-, or Panuveitis

NCT01781936
View directory record Official record
Conditions
Uveitis Affecting the Posterior Segment
Interventions
Fluocinolone Acetonide
Drug
Lead sponsor
Glenn Jaffe
Other
Eligibility
Not listed
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 20, 2019 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Safety and Exploratory Skin Lesion Measurement of TR-701 FA Study

NCT01519778
View directory record Official record
Conditions
Major Cutaneous Abscess, Cellulitis, Erysipelas
Interventions
TR701 FA
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
10
States / cities
Anaheim, California • Buena Park, California • Chula Vista, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 20, 2026, 4:46 PM EDT
Active, not recruiting Phase 2 Interventional

Seal, Stopping Eczema and Allergy Study

NCT03742414
View directory record Official record
Conditions
Eczema, Infantile, Eczema, Atopic Dermatitis Eczema, Atopic Dermatitis
Interventions
Tri-lipid skin barrier cream (Epiceram), Fluticasone propionate Cream 0.05%, Standard of Care
Combination Product · Other
Lead sponsor
Kari Nadeau, MD, PhD
Other
Eligibility
1 Week to 12 Weeks
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
4
States / cities
Palo Alto, California • Denver, Colorado • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 20, 2026, 4:46 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Instrumented Data Exchange for Ataxia Study

NCT04268147
View directory record Official record
Conditions
Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 2, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 6, Friedreich Ataxia
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
12 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Oct 20, 2026, 4:46 PM EDT
Terminated Phase 3 Interventional Results available

Preventive Treatment of Oxaliplatin Induced Peripheral Neuropathy in Metastatic Colorectal Cancer (POLAR-M)

NCT03654729
View directory record Official record
Conditions
Colorectal Cancer, Chemotherapy-induced Peripheral Neuropathy
Interventions
Calmangafodipir (2 µmol/kg), Calmangafodipir (5 µmol/kg), Placebo
Drug
Lead sponsor
Egetis Therapeutics AB (publ)
Industry
Eligibility
18 Years and older
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Fresno, California • Orange City, Florida • Wichita, Kansas + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Phase 2 Interventional

Safety and Efficacy of EPI-743 in Patients With Friedreich's Ataxia

NCT01728064
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
Placebo, EPI-743 400 mg, EPI-743 200 mg
Drug
Lead sponsor
PTC Therapeutics
Industry
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
3
States / cities
Los Angeles, California • Tampa, Florida • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Oct 20, 2026, 4:46 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

PET Imaging Study of α7 and α4β2-nAChR in Schizophrenia

NCT05462340
View directory record Official record
Conditions
Schizophrenia
Interventions
[18F]ASEM, [18F]AZAN
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
117 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 3, 2025 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Phase 1 Interventional

A Pharmacokinetics and Safety Study in Subjects With Renal Impairment

NCT01452828
View directory record Official record
Conditions
Renal Impairment
Interventions
TR-701 FA single infusion, TR-701 FA
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
2
States / cities
Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 3, 2016 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A PK and Safety Study in Subjects With Hepatic Impairment

NCT01431833
View directory record Official record
Conditions
Hepatic Impairment
Interventions
TR-701 FA
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 70 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
2
States / cities
Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 20, 2016 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mechanisms of Sleep Disruption Hyperalgesia

NCT01794689
View directory record Official record
Conditions
Sleep Deprivation, Pain
Interventions
Morphine, Saline Placebo, Forced Awakenings, Uninterrupted Sleep
Drug · Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 48 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Oct 20, 2026, 4:46 PM EDT
Not yet recruiting Phase 2 Interventional

GV101 for Friedreich's Ataxia (FA) Treatment

NCT07870590
View directory record Official record
Conditions
Friedreich's Ataxia
Interventions
GV101, Placebo
Drug
Lead sponsor
Graviton Bioscience Corporation
Industry
Eligibility
16 Years to 40 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Eatontown, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 20, 2026, 4:46 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Nicotinic Hepatic Metabolism on Neuroreceptor Substrates of Nicotine Addiction

NCT03442413
View directory record Official record
Conditions
Smoking, Tobacco
Interventions
2-[18F]-FA PET/CT, I.V. Nicotine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety, and Tolerability of TR-701 Free Acid (FA) in Elderly Subjects

NCT01496677
View directory record Official record
Conditions
Healthy Subjects
Interventions
TR-701 FA 200 mg
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 20, 2026, 4:46 PM EDT
Completed No phase listed Observational

Nicotinic Receptor Levels After Stopping Smoking

NCT01704573
View directory record Official record
Conditions
Nicotine Addiction
Interventions
2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 16, 2017 · Synced Oct 20, 2026, 4:46 PM EDT
Completed Phase 3 Interventional Results available

Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization

NCT00436553
View directory record Official record
Conditions
Macular Degeneration, Choroidal Neovascularization
Interventions
Verteporfin Photodynamic Therapy, Ranibizumab, Verteporfin Placebo, Ranibizumab Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
50 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
36
States / cities
Tucson, Arizona • Beverly Hills, California • Oakland, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 20, 2026, 4:46 PM EDT
Recruiting No phase listed Observational

Longitudinal Natural History Study of Retinal Function in Eyes of Patients With Diabetes

NCT07270133
View directory record Official record
Conditions
Diabetic Retinal Disease
Interventions
Visual Acuity, Reading Speed, Visual Field testing, Contrast sensitivity, Electroretinography (ERG) and pupillography in light- and dark-adapted states, Ultrawide field-color photograph, Ultrawide field-Fluorescein angiogram, Optical coherence tomography, Optical coherence tomography- Angiography
Diagnostic Test · Other
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
6
States / cities
Augusta, Georgia • Boston, Massachusetts • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 20, 2026, 4:46 PM EDT
Recruiting No phase listed Observational

Image Evaluation of Intalight Dream OCTA Scans With Optos FA & ICGA Images

NCT07568704
View directory record Official record
Conditions
Retina Pathology
Interventions
Dream OCT
Device
Lead sponsor
Intalight, Inc
Industry
Eligibility
22 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 20, 2026, 4:46 PM EDT
Recruiting No phase listed Observational

A Study to Learn How BIIB141 (Omaveloxolone) Affects the Health of Participants With Friedrich's Ataxia Who Took it During Pregnancy and/or During Breastfeeding and About the Health of Their Babies

NCT06628687
View directory record Official record
Conditions
Friedreich Ataxia
Interventions
Omaveloxolone
Drug
Lead sponsor
Biogen
Industry
Eligibility
16 Years and older · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Morrisville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 20, 2026, 4:46 PM EDT